We then assessed the two compounds in cellular models of diffuse large B‐cell lymphoma (DLBCL), in which a synthetic lethal interaction between CBP and p300 has been described.[7, 21] Inhibition of CBP catalytic activity resulted in decreased cancer cell viability.[7, 10] Nevertheless, given the involvement of both the catalytic and scaffolding roles of CBP and p300 in promoting cancer cell growth, abolishing both of them via targeted degradation may represent a successful strategy. The gene discussed is EP300; the disease is diffuse large B-cell lymphoma.